New treatment may address imatinib-resistant tumors

Each year, 3,000 to 6,000 people are diagnosed with gastrointestinal stromal tumor (GIST)—the most common sarcoma of the gastrointestinal tract. Imatinib myeslate, or Gleevec®, has proved to be a...